Overview

This trial is active, not recruiting.

Condition multiple sclerosis
Treatment neuromodulation rehabilitation
Sponsor University of Wisconsin, Madison
Start date March 2014
End date March 2017
Trial size 6 participants
Trial identifier NCT02252666, 2013-1060

Summary

The investigators hypothesis is that electrical stimulation to the tongue that directly stimulates two cranial nerve nuclei (Trigeminal and Facial Nerve Nuclei), will excite neural impulses to the brainstem and cerebellum. The investigators call this cranial nerve non-invasive neuromodulation (CN-NINM). The activation of these structures induces neuroplasticity when combined with specific physical exercises, can reduce symptoms of advanced MS, targeting primarily postural stability (sitting and standing), upper extremity movement, and ability to perform self-transfers.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
neuromodulation rehabilitation Cranial Nerve Non-invasive Neuromodulation (CN-NINM)
CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.

Primary Outcomes

Measure
Trunk Impairment Scale (TIS)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months

Secondary Outcomes

Measure
Static Standing Balance Test
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Video Nystagmography (VNG)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Impact of Visual Impairment Scale (IVIS)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Medical Outcomes Study (MOS) Pain Effects Scale (PES)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Bladder Control Scale (BLCS) and Bowel Control Scale (BWCS)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Walking Distance and Speed
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
12-item MS Walking Scale (MSWS-12)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Box & Blocks (B&B) assessment
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Multiple Sclerosis Impact Scale (MSIS-29)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Modified Fatigue Impact Scale (MFIS)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Gross Motor Function Measure (GMFM)
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Slump Test
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months
Modified Rivermead Mobility Index
time frame: Change from Baseline at 2, 7, 12, 17, 22 and 27 weeks, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 months

Eligibility Criteria

Male or female participants from 18 years up to 90 years old.

Inclusion Criteria: - Subjects must be age 18 or older. - Subjects will have a score between 6.5 to 7.5 on the Kurtzke Expanded Disability Status Scale (EDSS). The EDSS is a method of quantifying disability in people with multiple sclerosis. - Score of 6.5: needs constant bilateral support to walk 20 meters without resting. - Score of 7.0: unable to walk beyond five meters even with aid, and is essentially restricted to a wheelchair; wheels self and transfers alone, and is active in wheelchair about 12 hours a day. - Score of 7.5: unable to take more than a few steps and is restricted to wheelchair, and may need aid to transfer; wheels self, but may require a motorized chair for a full day's activities. - Subjects will have reached a plateau in an MS focused physical rehabilitation program in the 6 months prior to enrollment. - Requiring prior physical therapy will ensure that subjects have a core level of function that will allow them to participate in the study. - Requiring that subjects have reached a plateau will ensure that subjects' response to the intervention is due to the use of the device and not to the physical exercises alone. - Subjects who have participated in a physical rehabilitation program demonstrate that they are willing and able to commit to a rigorous training regimen. - Subjects will have a maximum score of 20 on the Trunk Impairment Scale (TIS). The TIS assesses static dynamic sitting balance and trunk coordination in a sitting position. A score of 20 or lower indicates that their ability to adequately maintain sitting posture is affected. - Subjects may have upper extremity involvement. - Subjects may have additional symptoms of nystagmus, dysarthria, sensory disturbance, pain, and/or bowel and bladder function. As they present, we will use appropriate assessments at baseline and successive study test points. - Subjects are their own legal guardians, and are able to understand and give informed consent. Exclusion Criteria: Subjects will have no major co-morbidities, especially neurological disorders, uncontrolled pain, hypertension or diabetes. All subjects, if on medications, will not have had any major changes in type or dosage in within 3 months of enrollment. Additionally, candidates will be excluded if they: - have Functional Systems Scores (FSS) 4 or greater for pyramidal, cerebellar, brainstem, and sensory functions; 3 or greater for bowel and bladder function; and 2 or greater for cerebral function; - are able to walk independently; - use tobacco products (these activities tend to reduce tactile sensitivity in the oral cavity); - have any oral abrasions, cuts, cold sores, piercings, tissue inflammation, or have had oral surgery within the previous 3 months; - have a pacemaker, or are identified as at-risk for cardiovascular events; - have a history of seizures; - have a communicable disease; - have a biomechanical prosthetic; - are females who are pregnant.

Additional Information

Official title Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)
Principal investigator Mitchell E Tyler, MS
Description The intervention will be similar to that used in the investigators previous work with movement disorders, and will be tailored to the address issues unique to individuals with advanced MS. The study will enroll a total of 6 subjects having advanced MS that present with significant seated and standing balance, posture, or movement control deficits due to MS. Subjects will complete twice-daily lab training for two weeks (5 days/week). Each lab training (morning and afternoon) includes 1.5 to 2 hours of instruction in balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training. Activities are performed in 20-minute sessions with concomitant electrical stimulation of the tongue. The intervention is customized according to each subject's particular symptoms and tolerance. If a subject is not able to perform this amount of training, the training will be adapted to a level that is tolerable. After these 2 weeks, subjects will continue to perform these same intervention activities at home for 4 weeks. They will return to the lab for 1 week of training and testing, then perform home training for 4 weeks. This cycle is repeated for a total of 5 cycles. After the 6 months have been completed, subjects may choose to participate in an optional second phase of the study. The second phase includes an additional 12 months of participation in which subjects perform the intervention activities at home training and return to the lab on time per month for 2 hours of testing and 2 hours of training. If successful, this study would indicate that CN-NINM intervention may reduce the symptoms of advanced MS.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by University of Wisconsin, Madison.